利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.011 秒)

    NOVEL COMPOUNDS
    1.
    发明公开
    NOVEL COMPOUNDS 审中-公开

    公开(公告)号：EP4424315A2

    公开(公告)日：2024-09-04

    申请号：EP24159857.2

    申请日：2019-03-01

    申请人： Inflazome Limited

    发明人： COOPER, Matthew ,  MILLER, David ,  MACLEOD, Angus

    IPC分类号： A61K31/64

    CPC分类号： C07C311/60 ,  C07D295/096 ,  C07D213/34 ,  A61P29/00 ,  C07C2603/1020170501

    摘要： The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

    NOVEL COMPOUNDS
    2.
    发明公开
    NOVEL COMPOUNDS 审中-公开

    公开(公告)号：EP4417207A2

    公开(公告)日：2024-08-21

    申请号：EP24159911.7

    申请日：2019-03-01

    申请人： Inflazome Limited

    发明人： Cooper, Matthew ,  Miller, David ,  Macleod, Angus

    IPC分类号： A61K31/64

    CPC分类号： C07C311/60 ,  A61P29/00 ,  C07C2603/1020170501

    摘要： The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted either (i) at the ortho-position with a halo group, or (ii) at the meta- and para-positions, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted across the 2,3-positions with a fused ring and further substituted at the 4-position. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.